Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations
Authors:
- Jérôme MulhbacherJMJérôme Mulhbacher
- Éric NadeauÉNÉric Nadeau
- John Morris FairbrotherJFJohn Morris Fairbrother
- Mircea Alexandru MateescuMMMircea Alexandru Mateescu
- 1 May 2005
- journal article
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 60 (1) , 53-60
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Modified high amylose starch for immobilization of uricase for therapeutic applicationBiotechnology and Applied Biochemistry, 2002
- Immunomodulating activities of soluble synthetic polymer-bound drugsAdvanced Drug Delivery Reviews, 2002
- Cross-linked amylose tablets containing α-amylase: an enzymatically-controlled drug release systemJournal of Controlled Release, 1999
- Cross-linked amylose as matrix for drug controlled release. X-ray and FT-IR structural analysisCarbohydrate Polymers, 1998
- Parenteral vaccination of mice and piglets with F4+Escherichia coli suppresses the enteric anti-F4 response upon oral infectionVaccine, 1996
- Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide)Vaccine, 1993
- Adhesive fimbriae produced in vivo by Escherichia coli O139:K12 (B):H1 associated with enterotoxaemia in pigsVeterinary Microbiology, 1990
- Chemically-modified polysaccharides for enzymatically-controlled oral drug deliveryBiomaterials, 1990
- Protection against Enteric Disease caused by Escherichia coli–a Model for Vaccination with a Virulence Determinant?Nature, 1973
- Sur les enzymes amylolytiqucs III. La β‐amylase: dosage d'activité et contrôle de l'absence d'α‐amylaseHelvetica Chimica Acta, 1948